• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Research shows stem cell treatment could improve irregular heartbeat

March 2, 2017 By Sarah Faulkner

Research shows stem cell treatment could improve irregular heartbeatA study published in Stem Cells Translational Medicine showed that treating heart patients with mesenchymal stem cells does not increase their risk for irregular heart beat and instead improved the patients’ cardiac conditions.

Previous studies have shown that stem cells have the potential to repair the damage caused by heart disease, but there was speculation that some stem cells could worsen the condition in the same way that some anti-arrhythmia drugs do.

“This could be an important breakthrough for many heart patients, as proarrhythmia – which is a new or more frequent occurrence of pre-existing arrhythmia – unfortunately can be a side effect of some of the drugs we’re using to treat these patients,” lead author Dr. Raul Mitrani said in prepared remarks.

The team of researchers analyzed the data from 88 patients enrolled in 2 clinical trials evaluating the potential of mesenmchymal stem cells in treating ischemic cardiomyopathy.

A year after the patients began treatment, the patients who received mesenchymal stem cells showed no signs of arrythmia.

“We were encouraged by what we saw,” Mitrani said. “Even better, in a group of patients with low ventricular ectopy burden – what some call ‘heart hiccups’ or ‘skipped beats’ – there were definite signs of improvement while in the BMC and placebo groups, no similar signal for improvement was noted. This leads us to believe that prospective studies might clarify the role of MSCs to reduce ventricular arrhythmias.”

“By combining data from 2 studies, the authors were able to study this question in 1 of the largest groups of patients to date,” the journal’s editor-in-chief, Anthony Atlala, added. “These findings are important because they emphasize the need for further large prospective studies to evaluate the anti-arrhythmic potential of mesenchymal and other newer cell-based therapies.”

Filed Under: Cardiovascular, Featured, Regenerative Medicine, Research & Development, Stem Cells

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS